Oxcq 300 Tablet contains Hydroxychloroquine 300 mg, an antimalarial and immunomodulatory agent primarily used in the treatment and prevention of malaria, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine exerts its therapeutic effects by interfering with lysosomal activity and autophagy, modulating the immune response, and inhibiting the replication of certain pathogens. Oxcq 300 is indicated for acute and chronic malaria caused by Plasmodium species sensitive to hydroxychloroquine, and as a disease-modifying antirheumatic drug (DMARD) to reduce inflammation, pain, and joint damage in autoimmune conditions. The tablet should be administered orally, with dosing regimens tailored to the specific indication, patient weight, and clinical response, under medical supervision. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and skin rash. Long-term use requires monitoring for potential retinal toxicity through regular ophthalmologic examinations due to the risk of irreversible vision impairment. Caution is advised in patients with pre-existing retinal or visual field changes, hepatic or renal impairment, and in those taking concomitant medications that may prolong the QT interval. Oxcq 300 Tablet should be used strictly as prescribed, with adherence to recommended dosing to optimize therapeutic outcomes and minimize adverse effects.